186 related articles for article (PubMed ID: 33554038)
1. Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.
Iafolla MAJ; Yang C; Chandran V; Pintilie M; Li Q; Bedard PL; Hansen A; Lheureux S; Spreafico A; Razak AA; Hakgor S; Giesler A; Pugh TJ; Siu LL
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33554038
[TBL] [Abstract][Full Text] [Related]
2. Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types.
Chhibber A; Huang L; Zhang H; Xu J; Cristescu R; Liu X; Mehrotra DV; Shen J; Shaw PM; Hellmann MD; Snyder A
Immunity; 2022 Jan; 55(1):56-64.e4. PubMed ID: 34986342
[TBL] [Abstract][Full Text] [Related]
3. Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.
Lu Z; Chen H; Jiao X; Wang Y; Wu L; Sun H; Li S; Gong J; Li J; Zou J; Yang K; Hu Y; Mao B; Zhang L; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
Genome Med; 2021 Nov; 13(1):175. PubMed ID: 34732240
[TBL] [Abstract][Full Text] [Related]
4. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
[TBL] [Abstract][Full Text] [Related]
5. HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China.
Trachtenberg E; Vinson M; Hayes E; Hsu YM; Houtchens K; Erlich H; Klitz W; Hsia Y; Hollenbach J
Tissue Antigens; 2007 Dec; 70(6):455-63. PubMed ID: 17900288
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation and hitchhiking between structurally polymorphic Alu insertions and HLA-A, -B, and -C alleles and other retroelements within the MHC class I region.
Kulski JK; Shigenari A; Inoko H
Tissue Antigens; 2011 Nov; 78(5):359-77. PubMed ID: 21988723
[TBL] [Abstract][Full Text] [Related]
7. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
[TBL] [Abstract][Full Text] [Related]
9. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers.
Colen RR; Rolfo C; Ak M; Ayoub M; Ahmed S; Elshafeey N; Mamindla P; Zinn PO; Ng C; Vikram R; Bakas S; Peterson CB; Rodon Ahnert J; Subbiah V; Karp DD; Stephen B; Hajjar J; Naing A
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849924
[TBL] [Abstract][Full Text] [Related]
10. Regulation of HLA class I expression by non-coding gene variations.
Bettens F; Ongen H; Rey G; Buhler S; Calderin Sollet Z; Dermitzakis E; Villard J
PLoS Genet; 2022 Jun; 18(6):e1010212. PubMed ID: 35666741
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
12. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 alleles.
Currier JR; deSouza M; Chanbancherd P; Bernstein W; Birx DL; Cox JH
J Virol; 2002 May; 76(10):4971-86. PubMed ID: 11967314
[TBL] [Abstract][Full Text] [Related]
14. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.
Chowell D; Morris LGT; Grigg CM; Weber JK; Samstein RM; Makarov V; Kuo F; Kendall SM; Requena D; Riaz N; Greenbaum B; Carroll J; Garon E; Hyman DM; Zehir A; Solit D; Berger M; Zhou R; Rizvi NA; Chan TA
Science; 2018 Feb; 359(6375):582-587. PubMed ID: 29217585
[TBL] [Abstract][Full Text] [Related]
15. HLA class I antigen and HLA-A, -B, and -C haplotype frequencies in Uruguayans.
Alvarez I; Bengochea M; Toledo R; Carretto E; Hidalgo PC
Hum Biol; 2006 Aug; 78(4):513-25. PubMed ID: 17278625
[TBL] [Abstract][Full Text] [Related]
16. HLA-Cw*0409N is associated with HLA-A*2301 and HLA-B*4403-carrying haplotypes.
Pinto C; Smith AG; Larsen CE; Fernández-Viña M; Husain Z; Clavijo OP; Wang ZC; Nisperos B; Hansen JA; Alper CA; Yunis EJ
Hum Immunol; 2004 Feb; 65(2):181-7. PubMed ID: 14969773
[TBL] [Abstract][Full Text] [Related]
17. HLA class I diversity among rural rainforest inhabitants in Cameroon: identification of A*2612-B*4407 haplotype.
Torimiro JN; Carr JK; Wolfe ND; Karacki P; Martin MP; Gao X; Tamoufe U; Thomas A; Ngole EM; Birx DL; McCutchan FE; Burke DS; Carrington M
Tissue Antigens; 2006 Jan; 67(1):30-7. PubMed ID: 16451198
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the CD8
Killian MS; Teque F; Sudhagoni R
Immunogenetics; 2018 Feb; 70(2):99-113. PubMed ID: 28735348
[TBL] [Abstract][Full Text] [Related]
19. HLA class I associations with rates of HIV-1 seroconversion and disease progression in the Pumwani Sex Worker Cohort.
Peterson TA; Kimani J; Wachihi C; Bielawny T; Mendoza L; Thavaneswaran S; Narayansingh MJ; Kariri T; Liang B; Ball TB; Ngugi EN; Plummer FA; Luo M
Tissue Antigens; 2013 Feb; 81(2):93-107. PubMed ID: 23330720
[TBL] [Abstract][Full Text] [Related]
20. Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry.
Music M; Iafolla M; Soosaipillai A; Batruch I; Prassas I; Pintilie M; Hansen AR; Bedard PL; Lheureux S; Spreafico A; Razak AA; Siu LL; Diamandis EP
F1000Res; 2020; 9():337. PubMed ID: 33299547
[No Abstract] [Full Text] [Related]
[Next] [New Search]
